[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345817-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345817-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","co-exposure-to-lunasin-and-other-drugs-as-a-potential-chemopreventive-strategy-against-breast-and-colon-cancers-a-review","Co-Exposure to Lunasin and Other Drugs as a Potential Chemopreventive Strategy Against Breast and Colon Cancers: A Review","","More than 20 years after lunasin’s discovery, research has shifted from showing direct in vitro anticancer effects to improving bioavailability and evaluating lunasin as a potential adjunct to conventional cancer therapy. Lunasin, a soy-derived bioactive peptide, has been widely studied for antineoplastic activity, yet limited oral bioavailability has constrained clinical translation. Preclinical in vitro and in vivo findings suggest lunasin can enhance standard drugs in breast and colon cancers by sensitizing cells to apoptosis, modulating the cell cycle, reducing metastatic traits, and weakening drug-resistance signaling such as PI3K/Akt, FAK/MAPK1/NF-κB, and integrin-mediated pathways. Combination effects often occur at concentrations lower than effective monotherapy, indicating potential dose-reduction and adverse-effect mitigation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/co-exposure-to-lunasin-and-other-drugs-as-a-potential-chemopreventive-strategy-against-breast-and-colon-cancers-a-review/345817/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/co-exposure-to-lunasin-and-other-drugs-as-a-potential-chemopreventive-strategy-against-breast-and-colon-cancers-a-review/345817.png","ImageObject",300,407,{"name":42,"@type":43},"Eden","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why has lunasin research shifted over time?","Question",{"text":63,"@type":64},"Research has moved from studying direct in vitro anticancer activity toward approaches that address lunasin’s bioavailability and evaluate it as an adjunct in cancer therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limits lunasin’s clinical effectiveness?",{"text":68,"@type":64},"Limited oral bioavailability restricts its efficacy in clinical trials, motivating alternative strategies for use in humans.",{"name":70,"@type":61,"acceptedAnswer":71},"How does lunasin potentiate effects of standard anticancer drugs?",{"text":72,"@type":64},"In preclinical models, lunasin can enhance drug effects by sensitizing cancer cells to apoptosis, modulating cell cycle progression, reducing metastatic potential, and attenuating drug-resistance pathways such as PI3K/Akt and FAK/MAPK1/NF-κB.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345817,1790825628,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Review  \nCo-Exposure to Lunasin and Other Drugs as a Potential  \nChemopreventive Strategy Against Breast and Colon Cancers: A Review  \nAleksandra Janiak *, Agnieszka Kaufman-Szymczyk  and Katarzyna Lubecka-Gajewska   \nDepartment of Biomedical Chemistry, Faculty of Health Sciences, Medical University of Lodz, 92-215 Lodz, Poland; [agnieszka.kaufman-szymczyk@umed.lodz.pl](agnieszka.kaufman-szymczyk@umed.lodz.pl) (A.K.-S.); [katarzyna.lubecka@umed.lodz.pl](katarzyna.lubecka@umed.lodz.pl) (K.L.-G.)  \n* Correspondence: [aleksandra.janiak@umed.lodz.pl](aleksandra.janiak@umed.lodz.pl)  \nAbstract  \nMore than 20 years after the discovery of lunasin, a clear shift in lunasin research is observable—from an initial focus on its direct in vitro anticancer effects toward strategies aimed at improving its bioavailability and repositioning it as a potential adjunct in cancer therapy. Lunasin, a soy-derived bioactive peptide, has been extensively studied for its antineoplastic properties. However, its limited oral bioavailability restrains its efficacy in clinical trials. Therefore, recent research on lunasin points towards the possibility of using it as an adjunct in cancer treatment, rather than as a stand-alone nutraceutical in humans. In preclinical models, in vitro and in vivo, lunasin can enhance the effects of standard anticancer drugs in breast and colon cancers. Research suggests that lunasin can potentiate the effects of drugs, such as tamoxifen, aspirin, cisplatin, and oxaliplatin, by sensitizing cancer cells to apoptosis, modulating cell cycle progression, reducing metastatic potential, and attenuating drug-resistance pathways, including PI3K/Akt, FAK/MAPK1/NF-κB, and integrin-mediated signaling. In combination with those drugs, lunasin exerts significant anticancer effects at concentrations substantially lower than those proven as effective in monotherapy, suggesting a potential role in dose reduction in conventional agents and, subsequently, mitigation of their adverse effects. Although the enhanced effect of those combinations has been shown in preclinical models, there is a distinct lack of human clinical trials in this matter. Available evidence supports a promising concept of lunasin as a molecular “priming” agent that might complement cytotoxic therapies rather than replace them. This combination-oriented paradigm may represent a shift in lunasin research and offer a novel direction for the use of bioactive peptides in precision oncology; however, further studies exploring this possibility, including human clinical trials, are needed to elucidate lunasin’s role in nutraceutical-assisted cancer therapy.  \nAcademic Editor: Roberto Scatena  \nReceived: 21 May 2026  \nRevised: 25 June 2026  \nAccepted: 3 July 2026  \nPublished: 7 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nKeywords: lunasin; bioactive peptide; soy peptide; chemoprevention; adjunct; breast cancer; colon cancer  \n1. Introduction  \nCancer is one of the biggest problems for public health, with approximately 20 million new cases and 9.7 million deaths worldwide in 2022 . The most common are lung cancer (12.4% of all cancers—2.5 million cases), breast cancer (11.6%—2.3 million cases), and colorectal cancer (9.6%—1.9 million cases) . While lung cancer is characterized by the highest mortality rate, the breast and colorectal malignancies emerge as a clinical challenge;  \nbreast cancer is the most common cancer diagnosed in women, while colorectal cancer stands as the second leading cause of cancer-related mortality [1] .  \nBreast cancer is a group of malignancies that can be divided into three types, based on molecular and histological profile: hormone-positive, expressing estrogen or progesterone receptor (ER+ or PR+, respectively), expressing human epidermal receptor 2 (HER2+), and triple-negative bre","cbCaiszuzBsAf0WC","https://ap.wps.com/l/cbCaiszuzBsAf0WC","pdf",1614054,28,"English","# Introduction\n## Breast cancer background and risk factors\n## Colorectal cancer background and risk factors\n## Precision oncology and nutraceutical-assisted therapy","[{\"question\":\"Why has lunasin research shifted over time?\",\"answer\":\"Research has moved from studying direct in vitro anticancer activity toward approaches that address lunasin’s bioavailability and evaluate it as an adjunct in cancer therapy.\"},{\"question\":\"What limits lunasin’s clinical effectiveness?\",\"answer\":\"Limited oral bioavailability restricts its efficacy in clinical trials, motivating alternative strategies for use in humans.\"},{\"question\":\"How does lunasin potentiate effects of standard anticancer drugs?\",\"answer\":\"In preclinical models, lunasin can enhance drug effects by sensitizing cancer cells to apoptosis, modulating cell cycle progression, reducing metastatic potential, and attenuating drug-resistance pathways such as PI3K/Akt and FAK/MAPK1/NF-κB.\"}]","Co-Exposure to Lunasin and Other Drugs as a Potential Chemopreventive Strategy Against Breast and Colon Cancers: A Review | PDF",1790058969,71,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1843e35cc3cdf88d5543d54f7b10bd28.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3645b7116d0f89cfa802cbea07d8c20.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d2beaa0bccaa0de1882f6c5a0d33c70.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3828f482907f2d7676a9d4aff7e2db5c.webp",980,1385]